Today: 8 February 2026
Subscribe
Browse Category

NASDAQ:RZLT News 11 December 2025 - 24 December 2025

Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute, Inc. (RZLT) Stock News and Forecasts on Dec. 24, 2025: Phase 3 sunRIZE Miss, Analyst Target Cuts, and What Comes Next

Rezolute shares remain under pressure after the company’s December 11, 2025, announcement that its pivotal sunRIZE Phase 3 trial for ersodetug in congenital hyperinsulinism failed to meet primary and key secondary endpoints. The stock trades near $2.42, well below pre-trial levels, following analyst downgrades and investor-law-firm probes. Two serious hypersensitivity reactions were reported in the trial.
24 December 2025
··
Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts

Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts

Rezolute, Inc. (NASDAQ: RZLT) is one of the most closely watched biotech movers heading into the Dec. 12, 2025 session after a pivotal clinical trial miss triggered a historic repricing of the stock. As of the latest available trading update on Friday, December 12, 2025, Rezolute shares are trading around $1.40, down roughly $9.55 versus the prior close—about an 87% one-day collapse that has reset expectations across Wall Street. This article covers what happened, why it matters, where sell-side forecasts now stand (as of 12/12/2025), and what catalysts could still move Rezolute stock next. What happened to Rezolute stock: the
12 December 2025
US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns

US Stock Market Top Losers Today (December 11, 2025): Oracle’s AI Shock, Rezolute’s 88% Crash and Micro‑Cap Meltdowns

U.S. stocks closed mixed on Thursday, December 11, 2025, as a historic surge in the Dow clashed with a sharp tech sell‑off led by Oracle and a wave of brutal collapses in thinly traded micro‑caps. By the closing bell (4 p.m. ET), the Dow Jones Industrial Average was up roughly 1.3–1.4% and at a record high, while the S&P 500 edged about 0.1–0.2% higher. The Nasdaq Composite, however, slipped around 0.3–0.4%, dragged down by AI‑linked growth stocks.TradingView+2StockAnalysis+2 Under the surface, the real drama was in the top losers list, where failed drug trials, emergency capital raises, reverse stock splits and delisting threats combined into a textbook lesson on risk.
11 December 2025
····
Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage

Biggest Stock Losers Today in the U.S. Market (December 11, 2025): Oracle’s AI Reality Check, Rezolute’s Trial Disaster and Micro‑Cap Carnage

As Wall Street digests a fresh Federal Reserve rate cut and growing worries about an AI spending bubble, today’s U.S. stock tape is dominated by dramatic downside moves. From Oracle’s double‑digit plunge to biotech blow‑ups and reverse‑split micro‑caps, December 11, 2025 is one of the ugliest “losers lists” investors have seen this year. Below is a news‑driven breakdown of what’s happening, why these stocks are sinking, and what the day’s biggest losers say about the broader U.S. market. Key takeaways Market snapshot: Fed cut meets AI hangover According to StockAnalysis.com’s “Losers Today” dashboard, as of the latest update on December 11,
11 December 2025
····

Stock Market Today

Deutsche Telekom stock slips despite fresh buyback — what matters before earnings

Deutsche Telekom stock slips despite fresh buyback — what matters before earnings

8 February 2026
Deutsche Telekom shares fell 1.1% to 30.26 euros Friday, despite the company repurchasing 250,873 shares for about 7.63 million euros on Xetra. The drop came as European stocks rose and T-Mobile US shares slipped 2.2%. Deutsche Telekom’s 2025 results are due Feb. 26. The company has completed its 2025 buyback and launched a new 2 billion euro programme for 2026.
Airbus stock price ends higher near 191 euros as January deliveries slow, earnings loom

Airbus stock price ends higher near 191 euros as January deliveries slow, earnings loom

8 February 2026
Airbus shares rose 0.94% to 191.30 euros Friday as the company reported 19 aircraft deliveries in January, down from 25 a year earlier. Supply chain bottlenecks remain an issue, with executives at the Singapore Airshow calling delays “unacceptable.” Jefferies kept a Neutral rating and a 215-euro price target. Airbus will report full-year 2025 results on Feb. 19.
Go toTop